Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE).
Phase 1
Recruiting
- Conditions
- Eosinophilic Esophagitis
- Interventions
- Drug: EP-104GIOther: Matching vehicle control
- First Posted Date
- 2022-11-08
- Last Posted Date
- 2025-08-08
- Lead Sponsor
- Eupraxia Pharmaceuticals Inc.
- Target Recruit Count
- 117
- Registration Number
- NCT05608681
- Locations
- 🇦🇺
Campbelltown Private Hospital, Sydney, New South Wales, Australia
🇦🇺Eastern Health Box Hill, Box Hill, Victoria, Australia
🇦🇺Princess Alexandra Hospital, Brisbane, Queensland, Australia
Study to Evaluate the Efficacy and Safety of EP-104IAR in Patients With Osteoarthritis of the Knee
Phase 2
Completed
- Conditions
- Osteoarthritis, Knee
- Interventions
- Drug: EP-104IAR 25 mgDrug: Vehicle
- First Posted Date
- 2019-10-09
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Eupraxia Pharmaceuticals Inc.
- Target Recruit Count
- 318
- Registration Number
- NCT04120402
- Locations
- 🇨🇿
CCR Brno, s.r.o, Brno, Czechia
🇨🇿CCR Czech a.s, Pardubice, Czechia
🇨🇿CCR Prague, s.r.o, Prague, Czechia
Safety Study of a Long-Acting Injectable Steroid to Treat Knee Osteoarthritis
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2021-09-01
- Lead Sponsor
- Eupraxia Pharmaceuticals Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT02609126
- Locations
- 🇨🇦
Rebalance MD, Victoria, British Columbia, Canada
🇨🇦Centre for Studies in Family Medicine, London, Ontario, Canada
🇨🇦Fowler Kennedy Sports Medicine Clinic, London, Ontario, Canada
News
Eupraxia's DiffuSphere Technology Shows Targeted Drug Release in Phase 2a EoE Program
Eupraxia Pharmaceuticals' DiffuSphere technology demonstrates targeted drug release in a Phase 2a trial for Eosinophilic Esophagitis (EoE).